Premature ovarian insufficiency (POI)—formerly called premature ovarian failure—is cessation of ovarian hormone production and egg release before age 40, affecting approximately 1 in 100 women.
Premature ovarian insufficiency (POI)—formerly called premature ovarian failure—is cessation of ovarian hormone production and egg release before age 40, affecting approximately 1 in 100 women. Causes include genetic mutations (e.g., FMR1), autoimmune attack on follicles, chemotherapy or radiation damage, infection, or idiopathic (unknown) depletion of the primordial follicle pool. The result is infertility, oestrogen deficiency, and systemic menopausal symptoms despite young age. Current treatment is hormone replacement; fertility restoration is limited. Placental MSCs and fetal stem cells are being explored to regenerate follicle development or restore ovarian hormone production through direct cellular replacement, growth-factor secretion, and immunomodulation (suppressing anti-ovarian autoimmunity). Transplantation of cells into the ovary or systemic infusion aims to stimulate dormant follicles or create a regenerative microenvironment.
| Индикативна цена · България (ЕС) | €3,000–€8,000 |
|---|---|
| Глобален диапазон на пазарната цена | €6,440–€23,000 (placidway.com) |
| Основни видове клетки, които се изучават | MSCs from Amniotic Membrane, Fetal Stem Cells |
| Статус на одобрение | Експериментален |
| Регистрирани проучвания (ClinicalTrials.gov) | 35 · 3 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Thirty-five completed trials and 3 actively recruiting trials are registered for POI cell therapy, predominantly using autologous or allogeneic placental MSCs and fetal-derived cell preparations. Trial designs vary from direct ovarian injection to systemic intravenous infusion. Outcomes tracked include restored menstruation, improved hormone levels (oestradiol, FSH), pregnancy achievement, and ultrasound evidence of follicle development. Approximately 30–50% of treated women report return of menstrual cycles within 3–6 months; pregnancy rates (per cycle or per treatment) vary widely (10–40% in published small series) and are confounded by concurrent fertility treatments (in-vitro fertilisation, egg freezing).
Depending on assessment, a Premature Ovarian Insufficiency protocol may draw on:
POI cell therapy costs €4,500–8,000 per treatment, often requiring two to three infusions over a 6-month period. Additional fertility workup (hormone panel, ovarian ultrasound, sometimes egg retrieval and banking) adds €2,500–5,000. If fertility restoration is the goal, concurrent in-vitro fertilisation (IVF) can add €8,000–15,000, making total investment in combined POI cell therapy and fertility treatment €20,000–40,000 or more.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Premature Ovarian Insufficiency cost-by-country breakdown, or compare the best countries for Premature Ovarian Insufficiency →
Before booking, check safety & regulation, the recovery climate, дали бихте могли да бъдете кандидат, and which cell type fits Premature Ovarian Insufficiency.
Пълен Преждевременна овариална недостатъчност ЧЗВ → · Разбор на разходите Преждевременна овариална недостатъчност →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Съм ли кандидат? · Какъв тип клетки? · Types of clinics & best countries · Калкулатор на разходи
Медицински преглед от редакционния екип на StemCellAtlas с Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка